(Q38086264)

28 August 2017

title

Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis (English)

1 reference

28 August 2017

1 reference

1 reference

2

1 reference

28 August 2017

Abdulrahman A Aljumah

series ordinal

1

object named as

Abdulrahman A Aljumah

1 reference

28 August 2017

publication date

4 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

43

1 reference

28 August 2017

issue

12

1 reference

28 August 2017

page(s)

1255-1263

1 reference

Global epidemiology of hepatitis C virus infection

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Viral heterogeneity of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Interferon therapy in patients with chronic hepatitis C and schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a spanish center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12084

21 January 2018

Identifiers

DOI

10.1111/HEPR.12084

1 reference

28 August 2017

1 reference